Combination of | |
---|---|
Efgartigimod alfa | Neonatal Fc receptor blocker |
Hyaluronidase | Endoglycosidase |
Clinical data | |
Trade names | Vyvgart Hytrulo |
Other names | ARGX-113, Efgartigimod alfa/hyaluronidase-qvfc |
License data | |
Routes of administration | Subcutaneous |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Efgartigimod alfa/hyaluronidase, sold under the brand name Vyvgart Hytrulo, is a coformulation medication used for the treatment of generalized myasthenia gravis. [1] It contains efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase (human recombinant), an endoglycosidase. [1]
It was approved for medical use in the United States in June 2023. [2] [3]
Efgartigimod alfa/hyaluronidase is indicated for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive. [1]